Market News Call

Analyst’s Update: Amgen, Inc. (NASDAQ:AMGN), Gogo Inc (NASDAQ:GOGO)

UBS initiates Amgen, Inc.(NASDAQ:AMGN ) with a Neutral and price target of $185. During the next four years Amgen sales growth will face intensifying headwinds to Enbrel and key legacy products. The late-stage pipeline,

Just In: Celgene Corporation (NASDAQ:CELG), Incyte Corporation (NASDAQ:INCY)

UBS initiates Celgene Corporation(NASDAQ:CELG) with a Buy and price target of $140. Robust top-line growth has become a rarity in large-cap biotech, and against that backdrop, Celgene has and should continue to stand out

Stocks In News: Juno Therapeutics Inc (NASDAQ:JUNO), Broadcom Ltd (NASDAQ:AVGO)

Juno Therapeutics Inc(NASDAQ:JUNO) discontinues development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting   (25.31 +1.27) “We continue to experience encouraging signs of clinical benefit in our trial addressing

Puma Biotechnology Inc (NASDAQ:PBYI), Shake Shack Inc (NYSE:SHAK): What Analysts Are Saying After Today’s News?

Puma Biotechnology Inc(NASDAQ:PBYI). target lowered to $17 at RBC Capital Mkts; APHINITY hits; extended adjuvant is done; 3rd-line metastatic Phase III data 1H17  (38.05) RBC Capital Mkts lowers their PBYI tgt to $17 from $48.